ORLANDO, FL--(Marketwire - February 19, 2008) - Cardiovascular Sciences, Inc. (PINKSHEETS: CVSC) was established a few years ago to investigate and develop novel medical technologies to meet unmet and only partially addressed clinical needs. Areas of endeavor have required technologies as wide ranging as cell engineering to clot resistant coatings to tissue grafts to guided radiofrequency ablators and more. But what gradually became evident to the Company’s technical team as they considered a variety of factors such as the size and growth of the ultimate market, the shortfalls of available products for this need, and the resources and time required to develop a likely technology to marketability, there was one clinical need that trumped the other areas. That is the need to prevent adhesions and adhesion related complications that often follow various surgeries and traumas. The cost of these complications constitutes a $6+ billion global market. The adhesion process is part of normal healing and is what allows the edges of a cut on the skin to knit together and heal. But when two adjacent tissues that are not normally attached are stressed as happens in most surgeries, the surfaces can scar together and contract, causing problems ranging from minor discomfort to joint limitation to life threatening obstruction and intestinal perforation. The key to preventing this is to use a material to separate the surfaces for several days that then degrades and reabsorbs after the healing has reached the point after which adhesions are unlikely to occur.
